Autoantibodies As Biomarkers for Breast Cancer Diagnosis and Prognosis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Dec 1

PMID 36451832

Authors

Ruozhu Yang

Yi Han

Wenjun Yi

Qian Long

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most common cancer in women worldwide and is a substantial public health problem. Screening for breast cancer mainly relies on mammography, which leads to false positives and missed diagnoses and is especially non-sensitive for patients with small tumors and dense breasts. The prognosis of breast cancer is mainly classified by tumor, node, and metastasis (TNM) staging, but this method does not consider the molecular characteristics of the tumor. As the product of the immune response to tumor-associated antigens, autoantibodies can be detected in peripheral blood and can be used as noninvasive, presymptomatic, and low-cost biomarkers. Therefore, autoantibodies can provide a possible supplementary method for breast cancer screening and prognosis classification. This article introduces the methods used to detect peripheral blood autoantibodies and the research progress in the screening and prognosis of breast cancer made in recent years to provide a potential direction for the examination and treatment of breast cancer.

Citing Articles

A tumor-binding antibody with cross-reactivity to viral antigens.

Campa M, Gottlin E, Wiehe K, Patz Jr E Cancer Immunol Immunother. 2025; 74(4):126.

PMID: 40009215 PMC: 11865367. DOI: 10.1007/s00262-025-03975-8.

Use and Comparison of Machine Learning Techniques to Discern the Protein Patterns of Autoantibodies Present in Women with and without Breast Pathology.

Llaguno-Roque J, Barrientos-Martinez R, Acosta-Mesa H, Barranca-Enriquez A, Mezura-Montes E, Romo-Gonzalez T J Proteome Res. 2024; 24(1):289-302.

PMID: 39700258 PMC: 11705216. DOI: 10.1021/acs.jproteome.4c00759.

The clinical value of combined detection of seven lung cancer-related autoantibodies in assisting the diagnosis of non-small-cell lung cancer.

Chen G, Guo P, Zhao H, Zhao D, Yang D Biomark Med. 2024; 18(20):917-925.

PMID: 39360656 PMC: 11508994. DOI: 10.1080/17520363.2024.2404379.

Application of Intelligent Response Fluorescent Probe in Breast Cancer.

Sheng A, Zhang H, Li Q, Chen S, Wang Q Molecules. 2024; 29(18).

PMID: 39339288 PMC: 11434508. DOI: 10.3390/molecules29184294.

Autoantibodies in cancer: a systematic review of their clinical role in the most prevalent cancers.

Montero-Calle A, Garranzo-Asensio M, Moreno-Casbas M, Campuzano S, Barderas R Front Immunol. 2024; 15:1455602.

PMID: 39234247 PMC: 11371560. DOI: 10.3389/fimmu.2024.1455602.

References

Hattrup C, Gendler S . Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 2007; 70:431-57. DOI: 10.1146/annurev.physiol.70.113006.100659. View

Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R . Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A. 1995; 92(25):11810-3. PMC: 40492. DOI: 10.1073/pnas.92.25.11810. View

Sioud M, Hansen M, Dybwad A . Profiling the immune responses in patient sera with peptide and cDNA display libraries. Int J Mol Med. 2000; 6(2):123-8. DOI: 10.3892/ijmm.6.2.123. View

Donehower L, Harvey M, Slagle B, McArthur M, Montgomery Jr C, Butel J . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356(6366):215-21. DOI: 10.1038/356215a0. View

Hernandez Borrero L, El-Deiry W . Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. 2021; 1876(1):188556. PMC: 8730328. DOI: 10.1016/j.bbcan.2021.188556. View

Nazari S, Mukherjee P . An overview of mammographic density and its association with breast cancer. Breast Cancer. 2018; 25(3):259-267. PMC: 5906528. DOI: 10.1007/s12282-018-0857-5. View

Klade C, Voss T, Krystek E, Ahorn H, Zatloukal K, Pummer K . Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics. 2001; 1(7):890-8. DOI: 10.1002/1615-9861(200107)1:7<890::AID-PROT890>3.0.CO;2-Z. View

Metcalfe S, Wheeler T, Picken S, Negus S, Jo Milner A . P53 autoantibodies in 1006 patients followed up for breast cancer. Breast Cancer Res. 2000; 2(6):438-43. PMC: 13921. DOI: 10.1186/bcr91. View

Alberti G, Vergilio G, Paladino L, Barone R, Cappello F, de Macario E . The Chaperone System in Breast Cancer: Roles and Therapeutic Prospects of the Molecular Chaperones Hsp27, Hsp60, Hsp70, and Hsp90. Int J Mol Sci. 2022; 23(14). PMC: 9324353. DOI: 10.3390/ijms23147792. View

10.

Gotzsche P, Jorgensen K . Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013; (6):CD001877. PMC: 6464778. DOI: 10.1002/14651858.CD001877.pub5. View

11.

Liu W, Li Y, Wang B, Dai L, Qian W, Zhang J . Autoimmune Response to IGF2 mRNA-Binding Protein 2 (IMP2/p62) in Breast Cancer. Scand J Immunol. 2015; 81(6):502-7. PMC: 4431935. DOI: 10.1111/sji.12285. View

12.

Hofvind S, Ursin G, Tretli S, Sebuodegard S, Moller B . Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program. Cancer. 2013; 119(17):3106-12. PMC: 4288930. DOI: 10.1002/cncr.28174. View

13.

Rakha E, Boyce R, Abd El-Rehim D, Kurien T, Green A, Paish E . Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol. 2005; 18(10):1295-304. DOI: 10.1038/modpathol.3800445. View

14.

Wandall H, Blixt O, Tarp M, Pedersen J, Bennett E, Mandel U . Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res. 2010; 70(4):1306-13. PMC: 5538776. DOI: 10.1158/0008-5472.CAN-09-2893. View

15.

Hofvind S, Geller B, Skelly J, Vacek P . Sensitivity and specificity of mammographic screening as practised in Vermont and Norway. Br J Radiol. 2012; 85(1020):e1226-32. PMC: 3611728. DOI: 10.1259/bjr/15168178. View

16.

Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D . Autoantibody signatures in prostate cancer. N Engl J Med. 2005; 353(12):1224-35. DOI: 10.1056/NEJMoa051931. View

17.

Whitehouse C, Burchell J, Gschmeissner S, Brockhausen I, LLOYD K, Taylor-Papadimitriou J . A transfected sialyltransferase that is elevated in breast cancer and localizes to the medial/trans-Golgi apparatus inhibits the development of core-2-based O-glycans. J Cell Biol. 1997; 137(6):1229-41. PMC: 2132526. DOI: 10.1083/jcb.137.6.1229. View

18.

Lee P, Saraygord-Afshari N, Low T . The evolution of two-dimensional gel electrophoresis - from proteomics to emerging alternative applications. J Chromatogr A. 2019; 1615:460763. DOI: 10.1016/j.chroma.2019.460763. View

19.

Maselli A, Parlato S, Puglisi R, Raggi C, Spada M, Macchia D . Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer. Cells. 2019; 8(7). PMC: 6678306. DOI: 10.3390/cells8070750. View

20.

Feyzi-Barnaji B, Dinarvand R, Salehzadeh H, Arkan E, Salimi A, Nili F . Construction of a ternary nano-architecture based graphene oxide sheets, toward electrocatalytic determination of tumor-associated anti-p53 autoantibodies in human serum. Talanta. 2021; 230:122276. DOI: 10.1016/j.talanta.2021.122276. View